The Reverse Transcriptase Encoded by LINE-1 Retrotransposons in the Genesis, Progression, and Therapy of Cancer

Frontiers in Chemistry
I SciamannaC Spadafora

Abstract

In higher eukaryotic genomes, Long Interspersed Nuclear Element 1 (LINE-1) retrotransposons represent a large family of repeated genomic elements. They transpose using a reverse transcriptase (RT), which they encode as part of the ORF2p product. RT inhibition in cancer cells, either via RNA interference-dependent silencing of active LINE-1 elements, or using RT inhibitory drugs, reduces cancer cell proliferation, promotes their differentiation and antagonizes tumor progression in animal models. Indeed, the non-nucleoside RT inhibitor efavirenz has recently been tested in a phase II clinical trial with metastatic prostate cancer patients. An in-depth analysis of ORF2p in a mouse model of breast cancer showed ORF2p to be precociously expressed in precancerous lesions and highly abundant in advanced cancer stages, while being barely detectable in normal breast tissue, providing a rationale for the finding that RT-expressing tumors are therapeutically sensitive to RT inhibitors. We summarize mechanistic and gene profiling studies indicating that abundant LINE-1-derived RT can "sequester" RNA substrates for reverse transcription in tumor cells, entailing the formation of RNA:DNA hybrid molecules and impairing the overall production ...Continue Reading

References

Oct 31, 1991·Nature·M R WallaceF S Collins
Jun 27, 1970·Nature·H M Temin, S Mizutani
Apr 17, 1980·Nature·L E Orgel, F H Crick
Mar 22, 2000·The Journal of Cell Biology·R GiordanoC Spadafora
Mar 31, 2000·Nature Genetics·C EsnaultT Heidmann
Feb 7, 2001·Molecular and Cellular Biology·W WeiJ V Moran
Mar 10, 2001·Nature·E S LanderUNKNOWN International Human Genome Sequencing Consortium
Oct 2, 2001·Pharmacology & Therapeutics·M LeszczynieckaP B Fisher
Jun 27, 2002·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Christy R Hagan, Charles M Rudin
Aug 23, 2002·Seminars in Cancer Biology·Joseph Lotem, Leo Sachs
Apr 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Brook BrouhaHaig H Kazazian
Aug 5, 2003·Nature Genetics·Marie DewannieuxThierry Heidmann
Sep 23, 2003·Molecular Reproduction and Development·Carmine PittoggiCorrado Spadafora
Nov 25, 2003·American Journal of Human Genetics·Eric M OstertagHaig H Kazazian
May 8, 2004·Science·Gill BejeranoDavid Haussler
Aug 24, 2004·Oncogene·Rebecca NagyCharis Eng
Apr 5, 2005·Oncogene·Ilaria SciamannaCorrado Spadafora
Apr 9, 2005·Nucleic Acids Research·Jonathan PerreaultGilles Boire
Jun 10, 2005·Nature·Jun LuTodd R Golub
Dec 21, 2005·Molecular Reproduction and Development·Rosanna BeraldiCorrado Spadafora
May 24, 2006·Genome Research·Hidenori NishiharaNorihiro Okada
Jun 20, 2006·Nature Structural & Molecular Biology·Deanna A Kulpa, John V Moran
Aug 29, 2006·Nature Structural & Molecular Biology·Nuo Yang, Haig H Kazazian
Feb 20, 2007·Human Mutation·Daria V Babushok, Haig H Kazazian
Mar 17, 2007·Nature Reviews. Genetics·R Keith Slotkin, Robert Martienssen
May 1, 2007·Human Molecular Genetics·Jose L Garcia-PerezJohn V Moran
May 8, 2007·Human Molecular Genetics·José A J M van den HurkFrans P M Cremers
Feb 23, 2008·Chromosome Research : an International Journal on the Molecular, Supramolecular and Evolutionary Aspects of Chromosome Biology·Astrid BöhneJean-Nicolas Volff
Mar 28, 2008·Nature Reviews. Genetics·Cédric Feschotte
Aug 30, 2008·Genome Dynamics·P A Callinan, M A Batzer
Oct 16, 2008·Cell·John L Goodier, Haig H Kazazian
Jan 24, 2009·Nature Reviews. Molecular Cell Biology·V Narry KimMikiko C Siomi
Feb 12, 2009·PloS One·Stefan LehnertFrans C Schuit
Feb 26, 2009·Cell·Colin D Malone, Gregory J Hannon
Mar 25, 2009·Nature Reviews. Cancer·Christoph A Klein
Jun 3, 2009·Genes & Development·Hiroki KanoHaig H Kazazian
Aug 7, 2009·Nature·Nicole G CoufalFred H Gage
Nov 17, 2009·Current Opinion in Genetics & Development·Guillaume Bourque

❮ Previous
Next ❯

Citations

Jan 28, 2017·Journal of Experimental & Clinical Cancer Research : CR·Ayele Argaw-DenbobaClaudia Matteucci
Oct 1, 2017·Environmental Science and Pollution Research International·Anthony BertucciMagalie Baudrimont
Oct 5, 2018·Critical Reviews in Biochemistry and Molecular Biology·Jean-Hugues Guervilly, Pierre Henri Gaillard
May 10, 2016·Mobile DNA·Dustin C Hancks, Haig H Kazazian
Aug 27, 2019·Journal of Extracellular Vesicles·Yumi KawamuraTakahiro Ochiya
Jun 18, 2019·Journal of Experimental Neuroscience·Ming-Hsiang Lee, Jerold Chun
Feb 7, 2017·PloS One·Ioannis PapasotiriouPanagiotis Apostolou
Jun 23, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·P-T ChiouM G Casarotto
Nov 21, 2020·Mutagenesis·Nevio Cimolai
Sep 10, 2018·Trends in Genetics : TIG·Bhavana TiwariJohn M Abrams

❮ Previous
Next ❯

Methods Mentioned

BETA
Human Genome Sequencing
Human
transgenic

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.